Total Funding
53
65
Total FundingPost-IPO Equity raised
Growth Score
-2 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
11893
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Eric Devroe: SVP, Business OperationsPast Role: Opsonix, Founder & Chief Executive Officer
Kristina Masson: Co-Founder, Co-President, SVP of Global Operations, & Site Head of subsidiary
About the Company
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success. They specifically apply its approach to challenging oncology drug targets causally implicated in the vast majority of cancers, particularly those without simple single-gene driver mutations or synthetic lethal
contexts.
The company aims to rapidly progress in-licensed clinical-stage assets and a pipeline of internally developed programs through accelerated registration trials.
Women Founded
